Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Feb 28;14(2):676-678.
doi: 10.21037/tcr-24-1869. Epub 2025 Feb 26.

Accelerated hypofractionated chemoradiation followed by stereotactic ablative radiotherapy boost for locally advanced, unresectable non-small cell lung cancer

Urs M Weber  1 , Alexander S Watson  1 , Brian D Kavanagh  2 , Paul A Bunn  1
Affiliations
Editorial

Accelerated hypofractionated chemoradiation followed by stereotactic ablative radiotherapy boost for locally advanced, unresectable non-small cell lung cancer

Urs M Weber et al. Transl Cancer Res. .
No abstract available

Keywords: Stage III non-small cell lung cancer (stage III NSCLC); hypofractionated radiation; stereotactic body radiation therapy boost (SBRT boost).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-24-1869/coif). A.S.W. reports consulting fees from MJH Life Sciences LLC and receives payment/Honoria for lectures/presentations from Binaytara Foundation, Janssen Pharmaceuticals, and Nuvation Bio. The other authors have no conflicts of interest to declare.

Comment on

Similar articles

See all similar articles

References

    1. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med 2017;377:1919-29. 10.1056/NEJMoa1709937 - DOI - PubMed
    1. Spigel DR, Faivre-Finn C, Gray JE, et al. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol 2022;40:1301-11. 10.1200/JCO.21.01308 - DOI - PMC - PubMed
    1. Wu TC, Luterstein E, Neilsen BK, et al. Accelerated Hypofractionated Chemoradiation Followed by Stereotactic Ablative Radiotherapy Boost for Locally Advanced, Unresectable Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial. JAMA Oncol 2024;10:352-9. 10.1001/jamaoncol.2023.6033 - DOI - PMC - PubMed
    1. Ladbury CJ, Rusthoven CG, Camidge DR, et al. Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy. Int J Radiat Oncol Biol Phys 2019;105:346-55. 10.1016/j.ijrobp.2019.05.064 - DOI - PubMed
    1. Friedes C, Iocolano M, Lee SH, et al. Patterns of Failure, Low-Volume Relapse, and Subsequent Ablative Management in Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation and Consolidation Immune Checkpoint Inhibitors. Int J Radiat Oncol Biol Phys 2024;118:1435-44. 10.1016/j.ijrobp.2023.10.005 - DOI - PubMed

LinkOut - more resources